344 related articles for article (PubMed ID: 33634857)
21. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
23. Knowledge, attitude, and practice of cervical cancer screening among women living with HIV in the Kilimanjaro region, northern Tanzania.
Kimondo FC; Kajoka HD; Mwantake MR; Amour C; Mboya IB
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1374. PubMed ID: 33739611
[TBL] [Abstract][Full Text] [Related]
24. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
25. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study.
Xia C; Hu S; Xu X; Zhao X; Qiao Y; Broutet N; Canfell K; Hutubessy R; Zhao F
Lancet Public Health; 2019 Sep; 4(9):e462-e472. PubMed ID: 31493843
[TBL] [Abstract][Full Text] [Related]
26. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
27. Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer.
Arroyo Mühr LS; Gini A; Yilmaz E; Hassan SS; Lagheden C; Hultin E; Garcia Serrano A; Ure AE; Andersson H; Merino R; Elfström KM; Baussano I; Dillner J
Nat Commun; 2024 May; 15(1):3679. PubMed ID: 38693149
[TBL] [Abstract][Full Text] [Related]
28. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive approach to costing cervical cancer prevention and control: a case study in the United Republic of Tanzania using the Cervical Cancer Prevention and Control Costing (C4P) tool.
Levin A; Yuma S; Swai E; Morgan W; Gauvreau CL; Broutet N; Yeung KHT; Hutubessy R
BMC Med; 2022 Nov; 20(1):384. PubMed ID: 36316680
[TBL] [Abstract][Full Text] [Related]
30. Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand.
Smith MA; Hall M; Lew JB; Canfell K
Vaccine; 2018 Oct; 36(42):6314-6324. PubMed ID: 30224201
[TBL] [Abstract][Full Text] [Related]
31. Towards the global elimination of cervical cancer.
Canfell K
Papillomavirus Res; 2019 Dec; 8():100170. PubMed ID: 31176807
[TBL] [Abstract][Full Text] [Related]
32. Enhanced cervical cancer and HIV interventions reduce the disproportionate burden of cervical cancer cases among women living with HIV: A modeling analysis.
Broshkevitch CJ; Barnabas RV; Liu G; Palanee-Phillips T; Rao DW
PLoS One; 2024; 19(5):e0301997. PubMed ID: 38781268
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
34. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
[TBL] [Abstract][Full Text] [Related]
35. Brief Report: Modeling the Impact of Voluntary Medical Male Circumcision on Cervical Cancer in Uganda.
Davis SM; Habel MA; Pretorius C; Yu T; Toledo C; Farley T; Kabuye G; Samuelson J
J Acquir Immune Defic Syndr; 2021 Mar; 86(3):323-328. PubMed ID: 33136817
[TBL] [Abstract][Full Text] [Related]
36. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
37. No woman left behind: achieving cervical cancer elimination among women living with HIV.
Sharma K; Machalek DA; Toh ZQ; Amenu D; Muchengeti M; Ndlovu AK; Mremi A; Mchome B; Vallely AJ; Denny L; Rees H; Garland SM
Lancet HIV; 2023 Jun; 10(6):e412-e420. PubMed ID: 37182539
[TBL] [Abstract][Full Text] [Related]
38. Adolescent Health Series: HPV infection and vaccination in sub-Saharan Africa: 10 years of research in Tanzanian female adolescents - narrative review.
Whitworth H; Changalucha J; Baisley K; Watson-Jones D
Trop Med Int Health; 2021 Nov; 26(11):1345-1355. PubMed ID: 34310816
[TBL] [Abstract][Full Text] [Related]
39. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
40. Regional and country-level trends in cervical cancer screening coverage in sub-Saharan Africa: A systematic analysis of population-based surveys (2000-2020).
Yang L; Boily MC; Rönn MM; Obiri-Yeboah D; Morhason-Bello I; Meda N; Lompo O; Mayaud P; Pickles M; Brisson M; Hodgins C; Delany-Moretlwe S; Maheu-Giroux M
PLoS Med; 2023 Jan; 20(1):e1004143. PubMed ID: 36634119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
